Acumen Pharmaceuticals, Inc. (ABOS)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized gain (loss) on marketable securities | 8 | |||
| Research and development | 37,125 | |||
| General and administrative | 4,625 | |||
| Total operating expenses | 41,750 | |||
| Loss from operations | -41,750 | |||
| Other expense, net | -129 | |||
| Interest income | 2,015 | |||
| Interest expense | 1,046 | |||
| Change in fair value of embedded derivatives | -40 | |||
| Total other income | 800 | |||
| Net loss | -40,950 | |||
| Comprehensive loss | -40,942 | |||
| Net loss per common share, basic (in dollars per share) | -0.68 | |||
| Net loss per common share, diluted (in dollars per share) | -0.68 | |||
| Weighted-average shares outstanding diluted (in shares) | 60,573,425 | |||
| Weighted-average shares outstanding, basic (in shares) | 60,573,425 | |||